Cargando…
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505026/ https://www.ncbi.nlm.nih.gov/pubmed/36158826 http://dx.doi.org/10.3389/fcvm.2022.930797 |
_version_ | 1784796369769201664 |
---|---|
author | Quagliariello, Vincenzo Passariello, Margherita Di Mauro, Annabella Cipullo, Ciro Paccone, Andrea Barbieri, Antonio Palma, Giuseppe Luciano, Antonio Buccolo, Simona Bisceglia, Irma Canale, Maria Laura Gallucci, Giuseppina Inno, Alessandro De Lorenzo, Claudia Maurea, Nicola |
author_facet | Quagliariello, Vincenzo Passariello, Margherita Di Mauro, Annabella Cipullo, Ciro Paccone, Andrea Barbieri, Antonio Palma, Giuseppe Luciano, Antonio Buccolo, Simona Bisceglia, Irma Canale, Maria Laura Gallucci, Giuseppina Inno, Alessandro De Lorenzo, Claudia Maurea, Nicola |
author_sort | Quagliariello, Vincenzo |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed. METHODS: Firstly, in a human in vitro model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72 h. After treatment, production of DAMPs and 12 cytokines were analyzed in the supernatant through colorimetric and enzymatic assays. C57/Bl6 mice were treated with CTLA-4 or PD-1 blocking agents (15 mg/kg) for 10 days. Before (T0), after three days (T3) and after treatments (T10), ejection fraction, fractional shortening, radial and longitudinal strain were calculated by using bidimensional echocardiography (Vevo 2100, Fujfilm). Fibrosis, necrosis, hypertrophy and vascular NF-kB expression were analyzed through Immunohistochemistry. Myocardial expression of DAMPs (S100- Calgranulin, Fibronectin and Galectine-3), MyD88, NLRP3 and twelve cytokines have been analyzed. Systemic levels of SDF-1, IL-1β, and IL-6 were analyzed before, during and after ICIs therapy. RESULTS: Radial and longitudinal strain were decreased after 10 days of ICIs therapy. Histological analysis of NF-kB expression shows that short-term anti-CTLA-4 or anti-PD-1 treatment increased vascular and myocardial inflammation. No myocardial hypertrophy was seen with the exception of the pembrolizumab group. Myocardial fibrosis and expression of galectin-3, pro-collagen 1-α and MMP-9 were increased after treatment with all ICIs. Both anti-CTLA-4 or anti-PD-1 treatments increased the expression of DAMPs, NLRP3 inflammasome and MyD88 and induced both in vitro and in vivo the secretion of IL-1β, TNF-α and IL-6. Systemic levels of SDF-1, IL-1β and IL-6 were increased during and after treatment with ICIs. CONCLUSIONS: Short therapy with PD-1 and CTLA-4 blocking agents increases vascular expression of NF-kB, systemic SDF-1, IL-1β, IL-6 levels and myocardial NLRP3, MyD88 and DAMPs expression in preclinical models. A pro-inflammatory cytokine storm was induced in myocardial tissues and in cultured cardiac cells after ICIs therapy. The overall picture of the study suggests new putative biomarkers of ICIs-mediated systemic and myocardial damages potentially useful in clinical cardioncology. |
format | Online Article Text |
id | pubmed-9505026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95050262022-09-24 Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways Quagliariello, Vincenzo Passariello, Margherita Di Mauro, Annabella Cipullo, Ciro Paccone, Andrea Barbieri, Antonio Palma, Giuseppe Luciano, Antonio Buccolo, Simona Bisceglia, Irma Canale, Maria Laura Gallucci, Giuseppina Inno, Alessandro De Lorenzo, Claudia Maurea, Nicola Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed. METHODS: Firstly, in a human in vitro model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72 h. After treatment, production of DAMPs and 12 cytokines were analyzed in the supernatant through colorimetric and enzymatic assays. C57/Bl6 mice were treated with CTLA-4 or PD-1 blocking agents (15 mg/kg) for 10 days. Before (T0), after three days (T3) and after treatments (T10), ejection fraction, fractional shortening, radial and longitudinal strain were calculated by using bidimensional echocardiography (Vevo 2100, Fujfilm). Fibrosis, necrosis, hypertrophy and vascular NF-kB expression were analyzed through Immunohistochemistry. Myocardial expression of DAMPs (S100- Calgranulin, Fibronectin and Galectine-3), MyD88, NLRP3 and twelve cytokines have been analyzed. Systemic levels of SDF-1, IL-1β, and IL-6 were analyzed before, during and after ICIs therapy. RESULTS: Radial and longitudinal strain were decreased after 10 days of ICIs therapy. Histological analysis of NF-kB expression shows that short-term anti-CTLA-4 or anti-PD-1 treatment increased vascular and myocardial inflammation. No myocardial hypertrophy was seen with the exception of the pembrolizumab group. Myocardial fibrosis and expression of galectin-3, pro-collagen 1-α and MMP-9 were increased after treatment with all ICIs. Both anti-CTLA-4 or anti-PD-1 treatments increased the expression of DAMPs, NLRP3 inflammasome and MyD88 and induced both in vitro and in vivo the secretion of IL-1β, TNF-α and IL-6. Systemic levels of SDF-1, IL-1β and IL-6 were increased during and after treatment with ICIs. CONCLUSIONS: Short therapy with PD-1 and CTLA-4 blocking agents increases vascular expression of NF-kB, systemic SDF-1, IL-1β, IL-6 levels and myocardial NLRP3, MyD88 and DAMPs expression in preclinical models. A pro-inflammatory cytokine storm was induced in myocardial tissues and in cultured cardiac cells after ICIs therapy. The overall picture of the study suggests new putative biomarkers of ICIs-mediated systemic and myocardial damages potentially useful in clinical cardioncology. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9505026/ /pubmed/36158826 http://dx.doi.org/10.3389/fcvm.2022.930797 Text en Copyright © 2022 Quagliariello, Passariello, Di Mauro, Cipullo, Paccone, Barbieri, Palma, Luciano, Buccolo, Bisceglia, Canale, Gallucci, Inno, De Lorenzo and Maurea. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Quagliariello, Vincenzo Passariello, Margherita Di Mauro, Annabella Cipullo, Ciro Paccone, Andrea Barbieri, Antonio Palma, Giuseppe Luciano, Antonio Buccolo, Simona Bisceglia, Irma Canale, Maria Laura Gallucci, Giuseppina Inno, Alessandro De Lorenzo, Claudia Maurea, Nicola Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways |
title | Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways |
title_full | Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways |
title_fullStr | Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways |
title_full_unstemmed | Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways |
title_short | Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways |
title_sort | immune checkpoint inhibitor therapy increases systemic sdf-1, cardiac damps fibronectin-eda, s100/calgranulin, galectine-3, and nlrp3-myd88-chemokine pathways |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505026/ https://www.ncbi.nlm.nih.gov/pubmed/36158826 http://dx.doi.org/10.3389/fcvm.2022.930797 |
work_keys_str_mv | AT quagliariellovincenzo immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT passariellomargherita immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT dimauroannabella immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT cipullociro immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT pacconeandrea immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT barbieriantonio immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT palmagiuseppe immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT lucianoantonio immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT buccolosimona immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT biscegliairma immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT canalemarialaura immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT galluccigiuseppina immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT innoalessandro immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT delorenzoclaudia immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways AT maureanicola immunecheckpointinhibitortherapyincreasessystemicsdf1cardiacdampsfibronectinedas100calgranulingalectine3andnlrp3myd88chemokinepathways |